Exelixis, Inc.

Unlock to Claim this listing
Add / Modify Company

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company’s products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin’s lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited.

Click to rate this company
[Total: 0 Average: 0]

3.6

Overall Excellence Rating

Industry

Healthcare

Category

Biotech & Pharmaceuticals

ESG/Ethical Impact

Exelixis is committed to conducting business in a way that respects our environment and the Earth’s changing climate. We have already incorporated many environmentally sustainable practices into our facilities and operations, and we plan to incorporate more of these practices as we continue to grow As part of this commitment, Exelixis recognizes that climate change threatens human safety and well-being on a dramatic scale. We feel all businesses — especially those like ours that are dedicated to human health — have a duty to minimize their impact on climate change and promote a long and prosperous future for all of Earth’s inhabitants.Exelixis nurtures a culture where all employees feel empowered to be their authentic selves. We respect and appreciate each employee’s unique perspective and experiences, and believe that celebrating, encouraging and supporting both similarities and differences contributes to our company mission. As a socially responsible company, we include sustainability measures in our annual corporate goals that inform the compensation of our executive officers. Specifically for 2021 and 2022, we focused considerable resources on our human capital management strategy and DEI initiatives that are expanded upon in the following section. There is still work to be done, but we are proud of the progress we have made. We take pride in our core corporate values to Be Exceptional, Excel for Patients and Exceed Together, and remain committed to fostering a culture where each and every employee feels a sense of belonging to the Exelixis team and our mission.At Exelixis, we recognize that our company will not be successful in its mission to treat and defeat cancer unless we operate on a solid foundation of good governance, corporate responsibility and accountability. We embed strong legal and regulatory compliance practices and oversight into our scientific and business activities so that these activities will be conducted in a legal and ethical manner, and in the best interests of all Exelixis’ stakeholders. We have created and work to uphold a rigorous culture of compliance at every level of our organization so that we can safely and effectively deliver on our ongoing mission. The Nominating and Corporate Governance Committee (NCGC) of the Exelixis Board of Directors is responsible for reviewing and assessing the Company’s corporate sustainability strategy and policies, including with respect to ESG matters, and for overseeing management in its implementation of ESG efforts. The Board’s Compensation Committee has oversight of our policies and strategies related to human capital management including, but not limited to, recruiting, retention, career development and progressions, management succession planning (other than CEO succession), diversity and employment practices.The Ethics Committee and its reporting subcommittees facilitate dynamic risk management throughout the company by maintaining close supervision of each element of our business and driving insights through regular risk-based reporting. We supplement that reporting with periodic “deep- dive” assessments in areas of business operations identified as higher risk. To complete these assessments, we retain the services of outside experts or counsel, ensuring both appropriate expertise and sufficient objectivity are brought to the task of evaluating the effectiveness of the relevant operational activity and its level of legal and regulatory compliance.Our Code of Conduct reflects the values that drive the performance of our business operations and describes how our officers, directors, employees and contractors are expected to conduct themselves when representing Exelixis. The Code of Conduct also underscores our commitment to comply with laws that regulate our business activities as a biotechnology company. We expect all our employees to understand and abide by our Code of Conduct and other relevant policies that are essential to their daily duties and our business. Each employee is trained on, and reviews and acknowledges, these policies in their initial onboarding; they then undergo refresher training on an annual basis.

Eligible Awards

Coming Soon

Claim Your Award Badges

Do you work with Us

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer.

Awards Received

2023

Revenues

$423,900,000.00

Website Traffic

Employee Rating

3

Customer Rating

3.7

Company Size

100-1000

ESG Risk Rating

3

We’re Happy to Help.

Do you have questions about your ranking, our projects, or why you’re not on the list?
Scroll to Top

Excellence In My Industry

This badge tells your customers, employees, partners, and other stakeholders that your company has met the criteria of our excellence certification in best practices across all pillars of business in your specific industry – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Best Practice Certified

This badge tells your customers, employees, partners, and other stakeholders that your company has met the criteria of our excellence certification in best practices across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Best of Best Practices

This badge tells your customers, employees, partners, and other stakeholders that your company is one of the top 20 companies in your industry that has met the criteria for our excellence certification in best practices across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Newsweek Excellence 1000

This badge tells your customers, employees, partners, and other stakeholders that your company is one of the Top 1000 companies that demonstrate excellence across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.